Cosentyx and Kesimpta Patient Assistance: an application guide for practices
Novartis runs patient assistance for Cosentyx and Kesimpta through a single enrollment form covering its patient assistance foundation range. It requires prescriber certification of the diagnosis, the patient’s consent and signature, and proof of household income. The form is published in English and Spanish.
Are you a patient? Start with the prescribing practice and use the official manufacturer link above for current program information. AlgoMeds cannot determine eligibility or check an application for you.
One application covers Cosentyx and Kesimpta
One document covers both, even though Cosentyx sits in dermatology and rheumatology while Kesimpta sits in neurology.
Each patient needs their own enrollment and the prescriber certifies the specific drug and diagnosis, but the form itself does not change between the two clinics.
English and Spanish versions exist, so a patient completes their section in the language they actually read rather than working through a translation at the counter.
| Brand | Generic | Used for | How it is given |
|---|---|---|---|
| Cosentyx | secukinumab | plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and hidradenitis suppurativa | Self-administered by the patient at home |
| Kesimpta | ofatumumab | relapsing forms of multiple sclerosis | Self-administered by the patient at home |
Eligibility factors to verify
Novartis sets the eligibility criteria for the Cosentyx and Kesimpta program and changes them, so the categories below are only the ones programs of this kind generally assess.They are not the criteria for this program, confirm current requirements onNovartis’s official program pagebefore telling a patient anything. We do not publish income thresholds for Cosentyx and Kesimpta here, because a stale number on a marketing page is how a practice ends up telling a patient the wrong thing.
- Insurance status, generally aimed at patients who are uninsured, or insured but unable to access the medication through their coverage.
- Household income against the program’s own published threshold, evidenced by documentation rather than attestation.
- Residency and prescriber licensure requirements set by the program.
- A prescription written for an indication the program covers, certified by the prescribing clinician.
What the application needs
A complete Cosentyx and Kesimpta application is assembled from the four parts below, and because Cosentyx and Kesimpta is self-administered by the patient at home, the part most likely to hold it up is the one this practice controls least. Missing any one of them is what sends a form back rather than forward.
| Part | Who owns it | What it contains |
|---|---|---|
| Prescriber section | Prescribing clinician | Diagnosis, treatment plan, prescribed regimen, prescriber credentials and NPI, and the certification signature. |
| Patient section | Patient or verified legal representative | Demographics, contact and shipping details, insurance status, household information, program consent and the patient’s signature. |
| Income documentation | Patient | Documentary evidence of household income, in whichever forms the program accepts. |
| Program-specific attachments | Practice | Whatever else this specific program requires. Requirements differ between programs and change over time. |
Where practices get stuck
Common workflow challenges for these programs:
- Both are self-injected and ship to the patient, so the practice loses visibility once product leaves, a supply gap is reported by the patient, if at all.
- Both are dosed monthly, which is frequent enough that an enrollment gap becomes a missed dose quickly.
- Cosentyx is available in more than one route of administration for some indications, so a practice may run two workflows under one brand name.
- Cosentyx indications span dermatology and rheumatology, so the prescriber attestation differs even when the drug does not.
- Kesimpta patients switching from an infused therapy are moving from a workflow the practice controls to one it does not.
How long an application takes
We do not publish a turnaround figure for Cosentyx and Kesimpta, because Novartis sets it and it moves. What a practice can control is the work before submission. Four factors commonly affect the timeline: how long the patient section takes to return, how many review cycles occur between staff and the prescriber, whether the submission is complete on the first attempt, and the manufacturer review time, which we do not estimate.
How AlgoMeds handles it for Cosentyx and Kesimpta
AlgoMeds opens the correct current Cosentyx form, including variant forms that depend on indication, already filled from the patient chart, prescriber profile, insurance on file and prior submitted applications. The patient signs from a single-use, identity-verified link sent by text message, with no account required. This can reduce printing and scanning. Required documents are checked before submission, the application is tracked to a decision, and renewals open ahead of expiry using information from the prior application.
For Cosentyx and Kesimpta, as for every program, AlgoMeds does not determine eligibility, predict approval, or claim to improve the odds of a decision going a particular way. It removes the paperwork between a clinical decision and a submittedCosentyx and Kesimpta application, nothing more, and nothing that touches the manufacturer’s judgement.See the full coordinator workflow.
Cosentyx and Kesimpta patient assistance: frequently asked questions
Does the route of administration change which form is used?
Programs sometimes use variant forms depending on how a product is administered. AlgoMeds resolves the correct current form and asks for a disambiguating detail only when the program genuinely requires one.
How are Spanish-speaking patients handled?
English and Spanish program forms are first-class in AlgoMeds, with curated clinical vocabulary rather than machine translation, so a patient completes their section in the language they actually read.
Related program guides
Practices working with this program may also work with these programs. See the full program directory, or thedermatology overview.
Cosentyx and Kesimpta are registered trademarks of Novartis or its affiliates. AlgoMeds is not affiliated with, endorsed by, or sponsored by Novartis. Program details are subject to change. Confirm current requirements with the official program before applying.
This page is general information for medical practices about a manufacturer program. It is not medical advice, not legal advice, and not a determination of eligibility. AlgoMeds does not host or reproduce manufacturer enrollment forms on this website.
Stop retyping the Cosentyx form.
Supported fields are filled from practice records, patients can sign from a text message, and staff can track each application from one workflow.